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Abstract  1 
Background: Optimal vascular function is vital for prevention of dementia. We 2 
hypothesised that elderly post-stroke (PS) survivors who maintain cognitive function 3 
(PSND) show unperturbed cerebral microvasculature, compared to those who become 4 
demented (PSD) or acquire other dementias.  5 
Methods: Using stereological spherical probe software, we compared changes in length 6 
density (Lv, cumulative vessel length per unit volume of tissue) of hippocampal 7 
microvasculature in post-mortem brain tissue from PS survivors, Alzheimer’s disease 8 
(AD), vascular dementia (VaD) and normal ageing control subjects. In addition, we 9 
assessed microvessel diameter in the same subjects. Microvasculature was identified by 10 
markers of endothelial cells (glucose transporter 1; GLUT1), basement membrane 11 
(collagen IV; COL4) and smooth muscle cells α-actin (SMA).  12 
Results: We found an increase in Lv of both GLUT1 and COL4 immunostained microvessels 13 
(p<0.05) in PSD and AD cases, compared to controls, PSND and VaD in the CA1. However, 14 
no changes were apparent in the CA2 region. Additional analysis revealed a significant 15 
increase in Lv in AD cases, compared to PSND and PSD, in the entorhinal cortex. 16 
Microvessel mean diameter was decreased in PSD, compared to PSND, as well as in AD 17 
and VaD, compared to controls. Cumulative frequency analysis of microvessel diameter 18 
showed that the PSND had a significantly greater proportion of vessels with diameters, 19 
ranging between 7 and 12 μm.  20 
Conclusions: An increase in microvascular Lv in AD and PSD suggests either an increase in 21 
angiogenesis or the formation of newer microvessel loops in response to cerebral 22 
hypoperfusion. A decrease in vessel diameter was also found in AD and VaD, suggesting 23 
increased vasoconstriction in dementia.  24 
  25 
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Introduction 1 
Previous epidemiological studies have shown that vascular disease plays a key role in the 2 
progression of dementia [1, 2], inclusive of cardiovascular risk factors, such as increased 3 
blood pressure [3], atrial fibrillation [4], diabetes mellitus [5] and other vascular disease-4 
related factors [6]. Studies using arterial spin labelling, have shown a reduction in cerebral 5 
blood flow (CBF) in the temporal lobe associated with dementia in Alzheimer’s disease (AD) 6 
[7] and in post-stroke (PS) survivors [8]. The decrease in CBF was believed to have been as a 7 
result of neurodegeneration in dementia, whereby the cerebral microvasculature is 8 
restricted or modulated due to lower demand for glucose and oxygen. However, an 9 
alternative view has also been proposed, where a decrease in CBF may be the cause or 10 
instigator of neurodegeneration [9]. Consistent with this hypothesis, we recently proposed 11 
there is a vascular basis for neuronal atrophy and likely neurodegeneration in post-stroke 12 
dementia (PSD) subjects without significant AD pathology [10]. 13 
The role of the cerebral microvasculature in age-related dementias still remains unclear. 14 
Using different methods of assessment, previous studies in dementia have suggested 15 
microvessel density, is decreased in dementia, especially in AD, [11-13], whereas others 16 
claim it is increased [14-16]. Some investigators have also demonstrated narrowing of 17 
microvessels in the CA1 of the hippocampus and entorhinal cortex (EC) of AD subjects [14, 18 
17]. Differences in the methods of analysis and brain regions investigated may explain the 19 
variable results. However, studies in AD have indicated that there is an up-regulation or 20 
modulation of pro-angiogenic proteins and vascular growth factors [18], which may increase 21 
the density of the microvasculature [19-21]. Studies involving transgenic (Tg) mice models, 22 
which over-express the amyloid precursor protein (APP) to simulate AD pathology, have 23 
reported decreased angiogenesis in the presence of amyloid β peptides [22]. Whilst a study 24 
using the Tg2576 mouse model found increased microvessel density and extensive 25 
disruption to tight junctions, leading to a new hypothesis of amyloidogenesis [23]. 26 
Additionally, a corrosion cast model of vasculature in an AD mouse model has suggested an 27 
increase in density, as well as degeneration, of vessels  [24]. Conversely, other studies, in an 28 
aged APP/PS1 mouse model, have shown no change in microvessel density [25].  29 
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To clarify these issues, we examined post-mortem tissue taken from the hippocampal 1 
formation to assess whether microvascular morphology, specifically length density (Lv) and 2 
diameter, was affected in different dementias, placing particular emphasis on PSD. The CA1 3 
subfield was assessed due to its importance in relation to the onset of dementia and specific 4 
susceptibility to both increased AD-like pathology, risk of ischaemia and hypoperfusion [26]. 5 
Lv measurements were conducted using a spherical probe [27] and the diameter of cerebral 6 
microvessels were assessed using software that had been developed to measure vessel 7 
diameter and perivascular space [28]. It is hypothesised that PSD cases will exhibit reduced 8 
microvascular density and diameter, compared to post-stroke non-demented (PSND). 9 
Preliminary analysis from this study was presented in abstract form at the 112th British 10 
Neuropathological Society Meeting, January 2011 [29]. 11 
 12 
Materials and methods 13 
Subjects and clinical features 14 
Post-mortem brain tissue was obtained from PSD and PSND subjects [30]. AD and vascular 15 
dementia (VaD) subjects and similar age controls were included for comparison. The 16 
demographic details of the different subjects are presented in Table 1. The post-stroke 17 
subjects were enrolled in the prospective Cognitive Function After Stroke (CogFAST) study 18 
[30, 31]. Stroke patients aged ≥75 years were selected on the basis that they were not 19 
demented three months post stroke and did not exhibit disabilities that would prevent them 20 
from completing cognitive testing. They received annual clinical assessments and a 21 
neuropsychological test battery from baseline, including the Cognitive Drug Research (CDR) 22 
battery, the Mini-Mental State Exam (MMSE) and the Cambridge Assessment of Mental 23 
Disorders in the Elderly (CAMCOG), which generated sub-scores for various cognitive 24 
domains, including memory and executive function [30, 32]. 25 
Subjects were classified as demented if they met DSM-IIIR criteria for dementia. 26 
Controls aged >75 years were only selected if they had not been diagnosed clinically with 27 
cognitive impairment. There was no significant difference between the groups in average 28 
survival time (59.4 months) post ischaemic injury event. Ethical approval was granted by 29 
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local research ethics committees for this study (Newcastle upon Tyne Hospitals Trust, UK) 1 
and permission for post-mortem research using brain tissue was granted for this project. All 2 
tissue was obtained from the Newcastle Brain Tissue Resource. 3 
Neuropathological examination 4 
Final classification of demented subjects was assigned based on established 5 
neuropathological diagnostic criteria [33]. Briefly, haematoxylin-eosin staining was used for 6 
assessment of structural integrity and infarcts, Nissl and luxol fast blue staining for cellular 7 
pattern and myelin loss, Bielschowsky’s silver impregnation for CERAD rating of neuritic 8 
plaques, and tau immunohistochemistry for Braak staging of neurofibrillary tangles. A 9 
diagnosis of VaD was made when there were multiple or cystic infarcts, lacunae, 10 
microinfarcts and small vessel disease, and Braak stage <III [33]. A diagnosis of AD was 11 
confirmed on evidence of significant Alzheimer’s- type pathology, namely a Braak stage V-VI 12 
score, a moderate-severe CERAD score and an absence of significant vascular pathology. 13 
Thal staging [34] was also performed: the hippocampal formation and medial temporal lobe 14 
were stained for amyloid (4G8 antibody) and each case was graded, dependent on staging 15 
criteria. Vascular pathology scores were derived from the presence of vascular lesions in 16 
brain areas, including the frontal lobe at the level of the olfactory bulbs, temporal lobe at 17 
level of the anterior hippocampus, and basal ganglia at level of mamillary body. Lesions 18 
including arteriolosclerosis, cerebral amyloid angiopathy, perivascular haemosiderin 19 
leakage, perivascular space dilatation in the deep and juxtacortical white matter (WM), 20 
myelin loss, and cortical micro (<0.5 cm) and large (>0.5 cm) infarcts were recorded with 21 
increasing severity resulting in greater scores [35]. Control subject tissue was determined 22 
not to have had sufficient pathology to reach threshold to ascertain a diagnosis for 23 
dementia (all pathological scores are shown in Table 1) 24 
Immunohistochemistry 25 
Paraffin wax-embedded human hippocampal blocks were selected based upon their 26 
proximity to a specific plane, adjacent to the anterior pole of the lateral geniculate body in 27 
the coronal plane, within the posterior section of the hippocampus. Due to limited access to 28 
tissue, as a result of working in the confines of a brain bank environment, only one block per 29 
case was available for analysis. For stereological analysis, 15 30-μm-thick serial sections 30 
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were cut from the front of the block and mounted onto Superfrost+ slides (Fisher Scientific, 1 
UK). Every fifth section was then chosen so that three sections per case were selected for 2 
uniform random sampling prior to staining with each of the markers for 3 
immunohistochemistry: glucose transporter 1 (GLUT1), collagen IV (COL4) and smooth 4 
muscle α-actin (SMA). Ten-μm-thick sections were used for vessel diameter analysis and 5 
mounted on 2% 3-aminopropyltriethoxysilane (APES) slides before being stained using a 6 
standard immunohistochemical technique for COL4. 7 
In the initial preliminary study, serially cut 10-μm-thick hippocampal sections taken 8 
from all dementia groups and controls (Table 1) were used to perform standard two-9 
dimensional analysis of the microvasculature and labelled with the same endothelial and 10 
basement membrane markers.  11 
  Antigen heat retrieval was conducted by placing the 30-µm-thick sections in boiling 12 
0.1M citrate buffer for 10-15 min. The primary antibodies used were as follows: GLUT1 13 
(ThermoScientific, UK, 1:200), COL4 (Sigma Aldrich, UK, 1:500) and SMA (Sigma Aldrich, UK, 14 
1:1000).  A protease antigen retrieval step was performed in the 10-μm-thick sections 15 
immunostained for COL4 by treating with 0.6% subtilisin A, type VIII bacterial protease 16 
(Sigma, UK) solution for 10 mins at room temperature. Appropriate secondary antibodies 17 
were used, followed by incubation with Vectastain Avidin/Biotinylated Complex (ABC) to 18 
increase sensitivity of staining (Vector Labs, UK). GLUT1, SMA and COL4 (10 μm) were 19 
visualised using 3,3’-diaminobenzidine and COL4 (30 μm) with Vector SG and counterstained 20 
with haematoxylin (Figure 1).  21 
Stereological and image analysis: length density and vessel diameter  22 
Initially, standard two-dimensional analysis was undertaken to assess trends in 23 
microvascular changes within various dementia groups [36]. However, to strengthen the 24 
preliminary findings and discern the three-dimensional aspect of the microvasculature, an 25 
adapted stereological protocol was used.  26 
The operators (MB, hippocampus and LN, EC) performed analysis blindly in order to restrict 27 
operator bias. Using the Stereologer2000 software (Stereologer, WV, USA), a spherical 28 
probe ‘space ball’ option was selected to measure Lv of microvasculature [27]. The operating 29 
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system was connected to a Zeiss Axiolab microscope with a motorised stage (Prior Scientific, 1 
UK).  2 
In this study, a spherical probe with a diameter of 18 μm was selected to allow for 3 
section shrinkage and an appropriate guard volume. An outline was drawn denoting the 4 
area of interest, which corresponded to the relevant hippocampal subfield or cortical region 5 
at low magnification (x5). Neuronal subfields were visualised with the aid of haematoxylin 6 
counter staining. A digitally generated, equally spaced grid was overlaid and used to ensure 7 
random sampling within x and y axis of the reference area. A pilot study was performed to 8 
determine the number of frames required to reduce the sampling coefficient of error (CE) to 9 
a satisfactory level. Such calculations were based on the density of vessels in a particular 10 
region, with the probe size and distance between probes altered accordingly. Lv was 11 
calculated by counting the number of intersections between the probe and the parameter  –12 
in this instance microvasculature (ΣQ), and the area of sampling probe (ΣA) (Lv = 2(ΣQ/ ΣA)) 13 
at x100 magnification (Mouton et al., 2002). The number of intersections was used to 14 
estimate the Lv for each case. As stated earlier, a lack of tissue availability prevented the full 15 
sampling of the region of interest, thus precluding the measurement of volume of the 16 
hippocampal structures and the subsequent calculation of total length using Lv estimates.  17 
Images for vessel diameter analysis were taken from 10-μm-thick sections stained 18 
with COL4 at x40 magnification using a Zeiss AX10 research-grade microscope from the CA1 19 
region. Approximately 30 images were taken at random across the area of interest in each 20 
case. Analysis of the vessel diameter was determined using  software developed to measure 21 
vessel diameter. The software was calibrated by measuring a known length from a graticule  22 
at the selected magnification of analysis [28]. Length was calculated by using digital 23 
generated lines drawn by the operator across the subject matter of interest. Each vessel was 24 
measured three times and the average from these measurements was recorded as the 25 
mean vessel diameter (Figure 1B). 26 
Statistical analysis 27 
Statistical analysis was carried out using IBM SPSS software (version 19.0). Significance was 28 
determined at p≤0.05. The Shapiro-Wilk test was used to test for normality of stereology 29 
data, parametric tests were used to analyse hippocampal data, and non-parametric tests 30 
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were used for EC data. Group means were compared using an ANOVA and Tukey post-hoc 1 
test, or Kruskal-Wallis and Mann-Whitney U test. Correlations were assessed using 2 
Pearson’s correlation. The Komolgrov-Smirnof test was used to assess the normality of 3 
vessel diameter data, as collective data was analysed from each group. Non-parametric 4 
Kruskal-Wallis test was used to analyse data and the Mann-Whitney U test was used to 5 
establish significance between groups. Cumulative frequency analysis was performed of 6 
increasing vessel diameter to determine if subpopulations of vessels were responsible for 7 
changes in mean. Comparisons between group cumulative frequencies and power analyses 8 
were carried out using Multitab 16 Statistical Software (Multitab Inc, USA).  9 
Results 10 
Neuropathological findings 11 
There were no significant differences in any of the pathological staging results between the 12 
PSND and PSD cases. Significant increases (P≤0.05) were apparent between the AD group 13 
and other disease groups for Braak stages, CERAD rating and Thal stages. The maximum Thal 14 
score that could be assigned to an individual case was stage four, due to the hippocampal 15 
formation and EC being the only regions assessed (Table 1). 16 
Length density assessment 17 
Initial assessment of hippocampal microvasculature was conducted using standard two-18 
dimensional image analysis with ImagePro 4.0 software (Mediacypernetics, USA). 10-μm-19 
thick sections were stained with GLUT1 and the data was represented as a percentage per 20 
area of staining in a total of 78 samples in all groups (Table 1). Significant increases in 21 
percentage per area were found in GLUT1 density in AD cases in the CA1, compared to PSND 22 
and PSD (p=0.011 and 0.037, respectively). A trend towards a significant decrease in GLUT1 23 
expression was found in PSND cases, compared to controls (p=0.073). A significant increase 24 
was also found in COL4 percentage per area in AD cases, compared to controls and VaD 25 
(p=0.024 and p=0.05, respectively). The only significant difference in CA2 was found with 26 
GLUT1, with an increase in AD compared to VaD (p=0.04). Based on these preliminary data, 27 
we wished to address issues surrounding microvascular orientation, stemming from the use 28 
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of two-dimensional analysis, which may have led to inaccurate conclusions. A modified 1 
stereological analysis was thus performed to estimate the microvascular Lv  (Table 1). 2 
The Lv results were normally distributed for all antibodies used in both the CA1 and 3 
CA2 regions (P>0.05). GLUT1 Lv, was significantly increased in the CA1 (p ≤ 0.001, F = 23.28). 4 
Significant increases in mean Lv in AD compared to all groups, except PSD (Figure 2A). There 5 
was no significant difference in Lv in the CA2 region (p = 0.459, F = 0.94).  6 
COL4 Lv followed a similar pattern to GLUT1 changes, predominantly labelling 7 
capillaries (Figure 1). In the CA1, differences were apparent between groups (p ≤ 0.001, F = 8 
14.92). A significant increase in Lv was observed between AD, compared to controls, PSND 9 
and VaD. Lv was significantly increased in PSD cases, compared to PSND and VaD. Similarly, 10 
in the CA2, as with GLUT1 Lv, there were no significant differences in COL4 (p = 0.443, F = 11 
0.98).  12 
As expected, SMA Lv was lower in all groups, compared to other vascular markers, 13 
due to its specificity for larger vessels (e.g. arterioles). Significant differences were apparent 14 
between the groups in the CA1 (p= 0.004, F = 5.22), where increases were observed in AD, 15 
compared to controls (AD mean Lv = 0.118 mm/mm-3 vs. controls mean Lv = 0.058 mm/mm-3, 16 
p=0.027) and VaD (mean Lv = 0.0475 mm/mm-3, p=0.004). No significant difference was 17 
observed in CA2 (p= 0.959, F = 0.15). SMA staining had a greater coefficient of error (CE) 18 
values in all CA fields due to the relative low vessel density of arterioles.  We found no 19 
correlation between Lv and age of subject, post-mortem delay or length of tissue fixation. 20 
The robustness of our Lv findings were verified by the strong correlation between GLUT1 21 
and COL4 in the CA1 (r2 = 0.687, p=0.000). This indicated internal consistency of the results 22 
obtained for individual microvascular Lv (Figure 2C). Thus, changes in Lv in the CA1 and lack 23 
of those in CA2 were reflected in both microvascular elements and profiles across all groups. 24 
We also performed analysis in the EC region within the same tissue sections to ascertain 25 
microvascular density changes in the neocortical region connected to the hippocampal 26 
formation. Given the similarity in expression between GLUT1 and COL4 found in the CA1, 27 
only GLUT1 Lv was analysed in the EC. We observed increases in AD cases, compared to 28 
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PSND (p=0.004). Additionally, PSD cases had significantly lower Lv than AD (p=0.016). PSND 1 
cases had significantly lower Lv, compared to controls (p=0.015).  2 
Measurement of microvessel diameters 3 
 A total of 4,082 microvessels were measured from all groups collectively for vessel 4 
diameter analysis. However, as there were differences in Lv between groups, the first 100 5 
microvessels randomly selected in each case were analysed and combined to calculate the 6 
mean vessel diameter for each group (Figure 1). AD and VaD groups exhibited the narrowest 7 
mean diameter (7.01 and 7.04 μm, respectively). The widest mean diameter was found in 8 
the PSND (8.03 μm). However, controls and PSD had similar mean diameters (7.47 and 7.44 9 
μm, respectively). After demonstrating that the data were non-parametric, we observed a 10 
significant difference between PSND and all other groups (p=0.000 for all groups). A 11 
significant difference was also found between controls and PSD, compared to AD and VaD 12 
(p=0.000 in all cases, Figure 3A). Group data were expressed in term of increasing diameter 13 
as cumulative frequency (Figure 3B). Significant differences were found between PSND 14 
compared to all other groups except VaD using χ2 distribution analysis (Table 2).  15 
Discussion 16 
Recent advances have shown that cerebral microvascular pathology is associated with age-17 
related cognitive decline [37-39]. Changes in microvessel morphology, including thinning 18 
[17] and increased tortuosity [36, 40], have been described in demented cases. Our results 19 
augment previous findings linking vascular pathology with cognitive decline by showing 20 
increased microvascular density in the CA1 in PSD, compared to PSND, in an endothelial cell 21 
(GLUT1) and basement membrane (COL4) markers. Such increases in Lv may be a reactive 22 
response, whereby increases in the perfusion surface between blood and brain result in 23 
remodelling of microvessels within a hypoxic environment. This interpretation does not 24 
counteract the notion that microvessel structural changes reflect increased tortuosity in PSD 25 
subjects. 26 
We also demonstrated significant increases in Lv in AD cases when compared against 27 
controls, PSND and VaD in the CA1 region, and with PSND and PSD in the EC region. This 28 
may relate to the presence of different components of AD pathology (see Supplementary 29 
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data), including amyloid plaques and neurofibrillary tangles [41]. However, our findings are 1 
consistent with previous studies showing an increase in Lv COL4 staining in the CA1 [16], as 2 
well as the temporal cortex [15] of AD cases. Our observations, which indicate no significant 3 
differences in the CA2 region, suggest that the increases in Lv are regionally-specific and can 4 
be attributed to increased vulnerability caused by AD pathology, or as a result of 5 
hypoperfusion, in the CA1 and EC. This appears to corroborate previous findings [42], which 6 
have indicated a selective reduction in capillary density within the CA1, but not the CA3 7 
region, albeit after acute ischaemic insults.  8 
Consistent with our previous work [40, 45], GLUT1 staining was not continuous along 9 
the vessel, unlike COL4 (Figure 1). This implied that the numbers of intersections recorded 10 
between the probe and the vessel may not have fully corresponded with GLUT-1 expression. 11 
We thus counteracted this issue by visualising vessels with a haematoxylin counterstain. 12 
Nevertheless, intersections were only recorded when other portions of the vessel were 13 
positively stained for GLUT1. The irregular staining of endothelial cells with GLUT1 along the 14 
vessel is likely to be due to cellular damage [45]. It is possible that the GLUT1 negative 15 
profiles, seen only with haematoxylin counterstaining, reflect reduced GLUT1 protein in 16 
cases with dementia [46-48]. 17 
We assessed SMA immunoreactivity, which predominately labelled smooth muscle 18 
cells within perforating branches of the hippocampal arterioles in CA1 and CA2. A significant 19 
increase in SMA Lv was found in CA1 in AD compared to controls and VaD; however, no 20 
difference was found between PSND and PSD.  21 
Previous neuroimaging studies have suggested that medial temporal lobe atrophy 22 
occurs in AD [49], as well as in PSD [50]. Thus, it could be argued that the observed increase 23 
in Lv in AD and PSD is an indicator of hippocampal atrophy or even tissue shrinkage, 24 
whereby loss of tissue reduces the distance between existing microvascular profiles [36]. 25 
Valid comparisons can be made of post-mortem tissue as all the tissues were treated in a 26 
standardised manner so any difference would be disease specific. In a related study [10], we 27 
found that hippocampal neuronal volume was decreased across all demented groups, 28 
thereby suggesting that hippocampal atrophy is not a unique finding to AD but is also 29 
apparent in PSD and VaD. Irrespective of such findings, the outcomes of the current study  30 
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did not concur with the notion that atrophy was the single factor leading to an increase in 1 
Lv, as we found a significant decrease in Lv in PSD cases in the EC compared to AD and no 2 
change in Lv in the CA1. If one hypothesises that atrophy is the only factor leading to 3 
increased Lv then one would expect similar findings in  both regions. Additionally, no change 4 
in Lv was observed in VaD cases, compared to control or PSND subjects. As atrophy could 5 
not be measured in the cases included in this study (MRI scans were not performed in all 6 
subjects who came to autopsy), it cannot be ruled out as a confounding factor. However, if 7 
the morphological changes were related to atrophy within the whole hippocampal 8 
formation or medial temporal lobe one would predict an increase in microvessel Lv, 9 
compared to PSND subjects in all regions and including VaD cases [51]. 10 
A technical limitation in this study was lack of availability of the whole reference 11 
volume (the hippocampus and EC) for cutting and sampling. The tissue was obtained from 12 
predefined blocks and as a result only one block per case was available for sampling. As a 13 
result of these inherent issues, we were unable to estimate volume of the hippocampus, 14 
meaning it was not possible to convert Lv into total length per structure (i.e. the 15 
hippocampus). As Lv is a measure that relies on the relationship between the numerator (in 16 
this case, the number of vessel intersections) and the denominator (the background 17 
neuronal tissue), this leaves open the possibility of ‘reference trap’ bias from tissue 18 
shrinkage as, if one assumes that the density of a component within a structure acts as a 19 
proxy for its total number, one must also make the assumption that the reference volume of 20 
the structure itself must remain unchanged across the groups measured. Though we cannot 21 
rule out the effects of shrinkage, all sections were processed identically and assessment of 22 
section thickness revealed no significant differences between groups making group effects 23 
unlikely. Whilst only six cases were analysed in each group, retrospective power analysis 24 
showed that there is a significant number of cases per group to obtain a high level of 25 
significant power.  26 
Consistent with previous studies [14,17], a significant decrease in vessel diameter was 27 
identified in AD and VaD. Possible string vessels [37, 45] were often observed but not 28 
quantified. These results may explain the commonly associated reduced CBF previously 29 
described in dementia and GLUT1 protein density [36]. A number of studies have suggested 30 
that amyloid β may play a direct role in increasing vasoconstriction [52] or that nitric oxide, 31 
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a natural vasodilator, is altered in dementia [53]. Another study has suggested that the 1 
vasoconstrictor endothelin-1 (ET-1) may play a role in both AD and VaD. However, changes 2 
in the mRNA of the endothelin converting enzyme (ECE-1) were small and increases found in 3 
ET-1 are most likely be caused by Aβ mediated up-regulation of the converting enzymes [54, 4 
55]. Furthermore, inhibiting angiotensin II, a potent vasoconstrictor may improve cognitive 5 
function in AD and VaD by ameliorating hypotension. However, angiotension II is also 6 
involved in inhibiting the release of acetylcholine and the up-regulation of inflammatory 7 
response [56, 57]. Patients with AD are less likely to have been prescribed angiotension II 8 
receptor blockers compared to age matched non demented controls [58], which may affect 9 
vessel diameter. Microvessel diameter was significantly increased in PSND, compared to 10 
controls and no significance difference was found between PSD and controls. The results 11 
outlined may thus either suggest that vessels in PSND are more vasoreactive and responsive 12 
to their environment after stroke and undergo re-modelling (unlike PSD cases), or, 13 
alternatively, that the vessel diameter may not be related to cognitive function post stroke.  14 
Cumulative frequency analysis showed that there were significant differences  in 15 
distribution analysis of increasing vessel diameter between the groups, suggesting variations 16 
in subpopulations of hippocampal microvessels. In the PSND group, vessel diameters were 17 
significantly wider than all the other groups. Cumulative frequency analysis suggested that 18 
there were greater proportions of vessels with a diameter (between approximately 7 and 12 19 
μm), compared to the other groups, and that the mean diameter increase was not caused 20 
by analysing a larger number of large vessels, including arterioles (Figure 3B). This could 21 
mean that the PSND group had microvasculature that is more adaptable in response to 22 
hypoperfusion. Distribution analysis showed that there was a significant difference between 23 
the PSND group and all other groups, except VaD. This suggests a significant variation in the 24 
composition of microvasculature across all groups.  25 
In summary, our results show an increase in microvascular Lv in PSD and AD and, 26 
furthermore, that microvessels were significantly wider in PSND cases. Moreover, there 27 
were differential microvascular changes across the regions of the hippocampus, with 28 
significant differences only found in the CA1 region. A significant increase was also observed 29 
in AD cases compared to both PSND and PSD in the EC. Given that there is an increase in Lv 30 
in PSD cases compared to PSND, but that they exhibit similar but minimal 31 
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neurodegenerative pathology, the microvascular changes found may be marker for 1 
hypoperfusion in PS survivors. Whilst there were no significant differences in Lv between 2 
PSND and VaD subjects, it is possible that the microvasculature attributes are similar in PSD 3 
and AD in the hippocampus (but not EC) but that different mechanisms occur in VaD. A 4 
significant increase in mean vascular diameter (between 7 and 12 μm) was also found in 5 
PSND cases, compared to other groups; however, there was no significant increase in the 6 
proportion of larger vessels i.e. arterioles. Furthermore, there was no significant difference 7 
in vessel diameter between controls and PSD suggesting that microvessels may not possess 8 
the ability to adapt to their environment and thus remained unaltered. It has been widely 9 
hypothesised that the decrease in diameter in AD and VaD would reduce CBF and increase 10 
brain hypoperfusion. This suggests that the increases in the proportion of small narrower 11 
vessels in AD and PSD, when compared to PSND, may be an indicator of new microvascular 12 
loops via angiogenic processes [23], or increased twisting of existing profiles [37]. However, 13 
alternative factors, such as atrophy, cannot be completely dismissed as a reason for the 14 
increases in microvascular density found in AD and PSD. 15 
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 1 
Table 1: Demographic details  2 
 Controls PSND PSD VaD AD 
Total number of 
controls or 
cases analysed 
13 23 13 15 14 
Age, y 
Mean (range) 
80.4 (72-94) 84.3 (78-94) 86.3 (80-96) 85.1 (71-97) 83.5 (70-91) 
PMD, h 
Mean (± 2SEM) 
28.0 (6.1) 45 (11.2) 47.2 (14.6) 35.0 (13.4) 59 (15.8) 
MMSE Score 
Mean (range) 
N/A 
27.1 (24-30) 17.3 (12-24) 
N/A N/A 
CAMCOG Score 
(range) 
N/A 
89.1 (82-99) 62.6 (24-80) 
N/A N/A 
Braak stage 
Mean (range) 
2.4 (1-4) 2.5 (1-5) 2.6 (0-4) 2.0 (1-4) 5.3 (4-6) 
CERAD 
Mean (Range) 
0.5 (0-1) 1.4 (0-2) 1.0 (0-3) 1.0 (0-2) 3.0 (3-3) 
    2.2 (0-4) 2.8 (1-4) 1.6 (0-4) 1.9 (0-3) 3.7 (3-4) 
22 
 
Vascular 
Pathology* 
(Range) 
NPD 12.6 (7-16) 11.9 (8-17) 13 (12-14) N/A 
Mean time from 
diagnosis of 
dementia to 
death (years) 
- - 2.38 4.58 4.0 
 1 
The causes of death included bronchopneumonia, cardiac arrest and carcinoma with no 2 
particular distribution in any group. The time period (weeks) of tissue fixation was in range 3 
8-15 weeks for all the cases.* Vascular pathology scores were derived as described 4 
previously [35]. For stereological analysis, six samples representing each disease type or 5 
controls were selected from the total pool and matched for age, post-mortem interval 6 
(PMD) and fixation length. Abbreviations: AD, Alzheimer’s disease; CAMCOG, Cambridge 7 
Assessment of Mental Disorders in the Elderly; CERAD Consortium to Establish a Registry for 8 
Alzheimer’s disease; MMSE, Mini-mental state exam; NPD, no neuropathological diagnosis; 9 
N/A not applicable PMD, post-mortem delay; PSND, post stroke non-demented; PSD, post-10 
stroke dementia; VaD vascular dementia.11 
23 
 
Table 2: Group differences between cumulative frequency distribution of vessel diameter 1 
 
Controls PSND PSD VaD AD 
Controls  49.11 (p≤0.001) 3.51 (N/S) 63.56 (p≤0.001) 0.535 (N/S) 
PSND 49.11 (p≤0.001)  23.74 (p≤0.001) 1.49 (N/S) 55.24 (p≤0.001) 
PSD 3.51 (N/S) 23.74 (p≤0.001)  34.90 (p≤0.001) 6.12 (p = 0.013) 
VaD 63.56 (p≤0.001) 1.49 (N/S) 34.90 (p≤0.001)  69.89 (p≤0.001) 
AD 0.535 (N/S) 55.24 (p≤0.001) 6.12 (p = 0.013) 69.89 (p≤0.001)  
 2 
Chi2 (χ2) distribution values and significant differences between the cumulative frequencies 3 
of vessel diameter. Analysis was performed using distribution analysis, with presumed 4 
distribution three parameter lognormal. N/S denotes no significant difference.  5 
 6 
 7 
 8 
  9 
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Figure legends: 1 
Figure 1 2 
Microvasculature in the CA1 region of the hippocampal formation. (A) Microvessels 3 
immunostained with GLUT1 antibodies for endothelial cells. (B) Microvessels and arterioles 4 
stained for basement membranes for COL4 (grey, arrow head) and smooth muscle α-actin 5 
(brown, open arrows). Note, GLUT1 stained microvessels appear discontinuous compared to 6 
COL4 (cf. A vs. B). C and D, Morphometric technique used to measure vasculature diameter 7 
stained with COL4 in 10 µm sections. (C) A longitudinal cut vessel and (D) a transectionally 8 
cut vessel. Magnification Bars: B=100 µm; C and D= 10 µm.  9 
 10 
 Figure 2    11 
Mean Lv values of GLUT1 and COL4 immunostained microvessels. Both markers (A and B) 12 
showed significant increases in Lv in AD and PSD groups in CA1 region. Significance: ** 13 
denotes p ≤ 0.01 and *** p ≤ 0.001, different means against AD (grey), PSD (black) and both 14 
AD and PSD (black bold). Results for CA2 region with no significant changes are not shown. 15 
C, The correlation between Lv of GLUT1 and Lv of COL4 immunostaining in CA1 showing 16 
internal consistency of measurement (r2 = 0.687, p=0.000). Key: AD, Alzheimer’s disease, 17 
controls, PSND, non-demented post-stroke subjects, PSD, post-stroke dementia and VaD, 18 
vascular dementia. 19 
 20 
Figure 3 21 
Microvessel diameters in PSD and AD versus controls. To standardise comparisons between 22 
disorders, due to increased microvessel densities in AD and PSD, the 1st one hundred vessels 23 
measured in each case were combined to calculate the mean vessel diameter in each group. 24 
*** denotes p ≤ 0.001. Bold black asterisks indicate significance between PSND and all other 25 
groups. Black asterisks indicate significant difference to PSD and grey asterisks show 26 
difference to controls. Bars represent 2 x SEM. C, Cumulative frequency of increasing vessel 27 
diameter between groups. The analysis allows to identify general trends in microvascular 28 
25 
 
changes within the population samples. Significant differences were found between PSND 1 
against controls, VaD, AD and PSD subjects (Table 2).  Abbreviations and key to symbols: AD, 2 
Alzheimer’s disease, PSND, non-demented post-stroke subjects, PSD, post-stroke dementia 3 
and VaD, vascular dementia. 4 
 5 
  6 
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Supplementary data 1 
The Lv values were also related to pathology, specifically Alzheimer-type, including Braak 2 
staging and Thal and CERAD scores. Braak scores were correlated with Lv in CA1 for GLUT1 3 
(0.540, p=0.004), COL4 (0.635, p=0.000) and SMA (0.455, p=0.020). Thal staging also showed 4 
a significant correlation in CA1 with GLUT1 (0.517, p=0.010) and COL4 (0.532 p=0.070). 5 
However, there was no correlation between Lv and SMA. CERAD scores were correlated with 6 
GLUT1 (0.501, p=0.015) and COL4 (0.540, p=0.008) in the CA1; a trend was also observed 7 
with SMA staining (0.406, p=0.054) (Table). There was no correlation observed between Lv 8 
values and any pathological substrate in the CA2.  9 
 Supplementary Table: The relationship of Lv with the burden of neuropathology 10 
 
Braak staging Thal et al staging CERAD scores 
Correlation 
Coefficient 
P 
value 
R2 
Correlation 
Coefficient 
P 
value 
R2 
Correlation 
Coefficient 
P 
value 
R2 
GLUT1 0.54 0.004 0.295 0.517 0.01 0.235 0.501 0.015 0.234 
COL4 0.635 0.000 0.403 0.532 0.007 0.283 0.540 0.008 0.292 
SMA 0.455 0.02 0.207 0.257 0.225 0.066 0.406 0.054 0.165 
 11 
There were significant correlations between increasing Lv and neuropathological scoring 12 
criteria for Braak staging, Thal staging and CERAD scores. The Lv was not significantly related 13 
to the vascular pathology scores for any of the groups (not shown). Abbreviations: COL4, 14 
collagen IV; GLUT1, glucose transporter 1; SMA, α-smooth muscle actin. 15 
 16 
 17 
